HARVARD BIOSCIENCE INC
For the period ended Dec 31, 2024. Filed Mar 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 14, 2025
HBIO$9.26+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
HARVARD BIOSCIENCE, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Net loss | $(12,405) | $(3,415) |
| Other comprehensive income (loss), net of tax: | ||
| Foreign currency translation adjustments | (1,405) | 1,507 |
| Defined benefit pension plans, net of tax benefit of $58 and $137, respectively | (175) | (446) |
| Derivative instruments qualifying as cash flow hedges, net of tax of $-0- | 100 | (199) |
| Other comprehensive (loss) income | (1,480) | 862 |
| Comprehensive loss | $(13,885) | $(2,553) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.